Stock Ratings / Health Care / VSTM / financials

RAPP (43) AMPH (71) AVLN (49) SPTX (56) ⌘ Pro Terminal →

Verastem Inc. (VSTM) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$9.66 -1.78% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $9.61

Verastem Inc. (VSTM) carries a Roarable Rating of E (Strong Sell) with 24/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (24/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $1.17B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $9.61 (-0.51%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (24/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.9% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-15.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for VSTM)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (24/100 Composite)

🔍 WHY VSTM SCORES 24/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+6/20 pts (25% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+6/20 pts (25% of score)

FRED Regime × Technicals: 84% of 52W Range • RSI-14 at 61.7 (BULLISH MOMENTUM)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$8.38+3.2% Next Q

Q2 (-2Q)

Grade E$8.65+16.1% Next Q

Q3 (-1Q)

Grade E$10.04-3.8% Next Q

Current

Grade E$9.66-10.9% Hist 90D α

Trajectory: E (16) → E (24)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a VSTM Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While VSTM currently carries a cautious 24/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($8.16) and Max Pain ($10.14) forces dealer call-delta covering toward $11.36.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $VSTM• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “VSTM Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 24%NO 76%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How VSTM Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $30.9M

FY24

Rev $10.0M

FY25

Rev $30.9M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$30.9M	52%	-80%	-$209.5M	-$137.5M	-45%
FY 2024	$10.0M	52%	-80%	-$130.6M	-$104.8M	-45%
FY 2023	$30.9M	52%	-297.9%	-$87.4M	-$86.5M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring VSTM)

✓Walkthrough of VSTM's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

VSTM // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +76.92%▲ ASCENDING CHANNEL

2026-10-30O $9.63H $9.92L $9.50C $9.66VOL 2.41M

RES: $10.32SUP: $6.97SMA50: $8.16SMA200: $6.17

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

VSTM Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 VSTM Butterfly Map → + Track VSTM →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +180.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on VSTM today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for VSTM. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for VSTM today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (VSTM)

Health Care Rank #994 of 1016 ⚔️ RAPP vs VSTM Full Matrix →

1. Head-to-Head Health Care Peer Comparison (VSTM vs. RAPP, AMPH, AVLN, SPTX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Verastem Inc. (VSTM) ranks #994 by composite RQD confidence (24/100, grade E) and #340 by equity capitalization ($1.17B). Within this direct 5-issuer industry benchmark cohort, AMPH leads on earnings valuation at 11.7x trailing P/E, while AMPH leads on capital efficiency and profitability with 9.0% ROIC and 49.5% gross margin. AMPH currently holds the highest overall quantitative score in the immediate peer group at 71/100 (B-) compared with VSTM at 24/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
VSTM ACTIVE Verastem Inc.	E	24/100	—	—	-35.0%	-1.78%	$1.17B	Benchmark Subject
RAPP Rapport Therapeutics Inc.	D-	43/100	—	—	-22.9%	+7.60%	$1.16B	/rapp-vs-vstm →
AMPH Amphastar Pharmaceuticals Inc.	B-	71/100	11.7x	49.5%	9.0%	+2.28%	$1.15B	/amph-vs-vstm →
AVLN Avalyn Pharma Inc.	D	49/100	—	—	—	-0.12%	$1.14B	/avln-vs-vstm →
SPTX Seaport Therapeutics Inc.	D+	56/100	—	—	—	+3.53%	$1.13B	/sptx-vs-vstm →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001526119

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Verastem Inc. (VSTM) reported GAAP revenue of $30.9M (+209.1% vs. FY2024 revenue of $10.0M ) , GAAP net income of -$209.5M, operating cash flow of -$137.5M, and free cash flow of -$137.5M (-31.2% YoY). On the balance sheet, VSTM closed FY2025 with $246.4M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$30.9M	-$209.5M	-$137.5M	-$137.5M	$246.4M	—
FY2024 (FY)	2024-12-31	$10.0M	-$130.6M	-$104.8M	-$104.8M	$101.5M	—
FY2023 (FY)	2023-12-31	$0	-$87.4M	-$86.5M	-$86.5M	—	—

3. VSTM Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is VSTM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Verastem Inc. (NASDAQ: VSTM) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 24/100 at a spot price of $9.66 (-1.78% 1D, market cap $1.17B). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, VSTM ranks #994 in composite RQD confidence.

How does VSTM compare to RAPP and AMPH in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), VSTM carries a Roarable E (24/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, RAPP (Rapport Therapeutics Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC -22.9%, cap $1.16B) and AMPH (Amphastar Pharmaceuticals Inc.) posts a B- grade (71/100 RQD, P/E 11.7x, ROIC 9.0%, cap $1.15B). Among the 5-stock peer group, AMPH leads on earnings multiple (11.7x) while AMPH leads on capital efficiency (9.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for VSTM?

Per VSTM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001526119), Verastem Inc. generated $30.9M in revenue (+209.1% YoY), -$209.5M in net income, and -$137.5M in free cash flow against $246.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is VSTM trading relative to its 50-day, 200-day, and 52-week technical levels?

VSTM last traded at $9.66 (-1.78% on volume of 1,939,781 shares), positioning the stock +18.38% above its 50-day simple moving average ($8.16) and +56.56% above its 200-day simple moving average ($6.17). Across its 52-week range of $3.43 to $10.82, VSTM sits at the 84.3% percentile with a 14-day RSI of 61.7 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($8.45 to $10.87).

VSTM Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is Verastem Inc. (VSTM)?

In FY 2025 (10-K), VSTM converted $30.9M of revenue into a 52% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Direct Sub-Reports: VSTM RQD Cockpit VSTM 12M Forecast VSTM Earnings & Move VSTM Dividends & DRIP VSTM Insiders & 13F VSTM Whale Options VSTM Profit Sankey VSTM News & Why